March 31, 2019
March 31, 2019
Singapore researchers have succeeded in coaxing the body’s own cells to kill a strain of liver cancer in two patients, by finding a way to control the behaviour of HBV-specific T cells, a type of immune cell.
Researchers say this new treatment is a potential game-changer for sufferers of Hepatocellular carcinoma (HCC), a form of liver cancer common in Asia.
According to the National Cancer Centre Singapore, liver cancer affects 24 out of every 100,000 people here. HCC is currently the most common type of primary liver cancer.
The treatment was developed in a collaboration between the Duke-NUS Medical School, the Singapore General Hospital, and biotechnology firm Lion TCR.
In it, white blood cells from a cancer patient are extracted and infused with receptors through a process lasting 10 to 14 days. Akin to putting spectacles on a person, these receptors boost the white blood cells, which are injected back into the patient, where they will identify cancer cells and attack them.
The treatment is tailor-made for each patient, taking into account an individual’s varying medical condition.
This project is a successful example of cell therapy, a field of study in which intact living cells are injected or implanted into a patient to restore tissue or organ function, or combat diseases such as cancer.
“White blood cells, in a patient with cancer, do not kill the cancer. We take out the white blood cells, and modify them in a laboratory under special, sterile conditions,” said Dr Tan Anthony Tanoto. “This changes the white blood cells from not being able to recognise cancerous tumours, to being able to target and kill cancerous growths.”
HCC is highly associated with the chronic hepatitis B virus. While small to moderate-sized tumours may be treated with surgery, liver transplants and radiology treatments, there is no cure for larger tumours.
“Treatment with drugs only helps moderately in the survival rate of patients with more serious cases of HCC,” said Prof. Antonio Bertoletti, Professor of the Emerging Infectious Diseases Programme at Duke-NUS, and founder of Lion TCR. “We were able to select, design and engineer individualised T cells for therapy. Our studies showed that these engineered T cells were able to destroy the tumour.”
During clinical trials, where over 20 cell infusions were performed on the two patients, the scientists found one patient had a reduction in his tumour size.
“Since white blood cells are produced in the human body, this form of treatment can not only destroy cancerous cells, but has no adverse side effects,” said Prof. Bertoletti. Neither patient experienced adverse reactions.
Prof. Bertoletti said the team would now work on improving the treatment, while making it more affordable and widely available. And some of the funding has been secured. Lion TCR will benefit from $80 million worth of funding from the Government for programmes that study, develop and scale up cell therapy projects.
“The therapy is expensive, as the cells are grown in a lab under absolutely sterile conditions. The cells will also be difficult to produce, as there is no ‘one size fits all’ version,” said Prof. Bertoletti.
“But it is our dream to make this treatment widely available, and affordable for more people.” The Straits Times
Lion TCR Receives FDA Fast Track Designation for its HBV-specific TCR T Cell Therapy for Hepatocellular Carcinoma
Scientific Founder & Chairman, Professor Antonio Bertoletti Has Been Placed on Highly Cited Researchers 2021 List
Lion TCR Announces FDA Clearance of its IND Application for its Lead Investigational Product, LioCyx-M004, for Hepatocellular Carcinoma
Scientific Founder, Prof Antonio Bertoletti Appointed as Cellular Immunotherapy Infectious Diseases Lead for Singhealth Duke-NUS Cell Therapy Centre
Lion TCR Licenses and Duke-NUS Medical School ink an exclusive IP licensing agreement for Immunosuppressive Drug Resistant Anti-Cancer T-cells
Dr Wai Lu-En, Director of R&D, represented Lion TCR to share the latest developments to the Minister for Manpower and Second Minister for Trade and Industry Tan See Leng.
Scientific Founder, Prof Antonio Bertoletti Appointed in Cell and Gene Therapy Workgroup in Singapore
Lion TCR Announces Data Presentation for its lead T-cell product, LioCyx-M at EASL Digital Liver Cancer Summit 2021
HSA approval for clinical trial for Lion TCR’s lead product LioCyx-M to characterize changes in liver cancer tumor microenvironment
Lion TCR presents two abstracts of Phase 1 clinical trial data for lead product LioCyx-M at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Companion diagnostic assay for personalised immunotherapy for HBV-related liver cancer featured in A*STAR GIS website
Singapore’s first clinical trial approval for T cell engineered (TCR) immunotherapy for treatment of Liver cancer
Lion TCR receives US$ 20 million to fund its personalized T cell therapy clinical trials against Liver cancer
Scientific Founder, Prof. Antonio Bertoletti and Scientific Consultant, Dr Anthony Tanoto Tan of Lion TCR were awarded the SingHealth Duke-NUS Research Award 1st Prize 2018
US FDA grants Lion TCR two orphan drug designations of T cell therapy against Hepatocellular Carcinoma
Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient